FDA Approves Galderma's Nemluvio as First IL-31 Inhibitor for Prurigo Nodularis
核心洞察
The FDA has approved Galderma's Nemluvio (nemolizumab) as the first IL-31 receptor (搜索) mAb for treating prurigo nodularis (搜索), a rare skin condition.
In Phase III trials, Nemluvio demonstrated a significant reduction in itch intensity compared to placebo, with results comparable to Dupixent.
Nemluvio offers a new treatment option for prurigo nodularis (搜索) patients, addressing a condition with limited existing therapies.
The FDA has granted approval to Galderma's Nemluvio (nemolizumab), making it the first IL-31 receptor (搜索) monoclonal antibody (mAb) available in the U.S. for the treatment of prurigo nodularis (搜索). This approval marks a significant advancement in treating the rare skin condition characterized by intensely itchy nodules.
Nemluvio's approval is based on data from the Phase III OLYMPIA 1 and OLYMPIA 2 trials. These studies demonstrated that 16 weeks of treatment with Nemluvio resulted in a clinically significant reduction in itch intensity for a substantial proportion of patients. Specifically, 56% and 49% of patients in the OLYMPIA 1 and OLYMPIA 2 trials, respectively, experienced at least a four-point reduction in itch intensity. This was compared to 16% in both studies' placebo groups (p<0.001).
The efficacy results of Nemluvio are similar to those observed with Dupixent (dupilumab), an IL-4 and IL-13 inhibitor from Sanofi, which was previously the only approved treatment for prurigo nodularis (搜索). In the Phase III PRIME trial for Dupixent, a four-point reduction in itch was seen in 44% of patients versus 15.8% for placebo at week 12 (p<0.001), increasing to 60% versus 18.4% at week 24 (p<0.001).
Prurigo nodularis (搜索) is a chronic, debilitating skin disease characterized by hard, intensely itchy nodules that can significantly impair quality of life. The approval of Nemluvio provides a valuable new option for patients who have had limited treatment alternatives. Galderma's Nemluvio offers a competitive alternative to Sanofi's Dupixent in the treatment landscape for prurigo nodularis.